Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients.
Malgorzata MikulskaChiara SepulcriChiara DentoneFederica MagneElisa BallettoFederico BaldiLaura LabateChiara RussoMichele MirabellaLaura MagnascoCarmen Di GraziaChiara GhiggiAnna Maria RaiolaDaniele Roberto GiacobbeAntonio VenaSabrina BeltraminiBianca BruzzoneRoberto M LemoliEmanuele AngelucciMatteo BassettiPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Combination therapy including two antivirals (mainly remdesivir and nirmatrelvir/ritonavir) and Mabs was associated with high rate of virological and clinical response in immunocompromised patients with prolonged/relapsed COVID-19.
Keyphrases
- combination therapy
- acute lymphoblastic leukemia
- end stage renal disease
- acute myeloid leukemia
- multiple myeloma
- coronavirus disease
- diffuse large b cell lymphoma
- newly diagnosed
- ejection fraction
- hodgkin lymphoma
- sars cov
- chronic kidney disease
- peritoneal dialysis
- hiv infected
- respiratory syndrome coronavirus
- patient reported outcomes
- hiv infected patients